Clinical aspects of psychopharmacology in childhood and adolescence / / Donald E. Greydanus ... [et al.], editors

• Record Nr.: UNINA9910809636003321
• Pubbl/distr/stampa: Hauppauge, NY, : Nova Science, c2011
• ISBN: 1-61122-715-1
• Edizione: [1st ed.]
• Descrizione fisica: 1 online resource (280 p.)
• Collana: Health and human development book series
• Altri autori (Persone): GreydanusDonald E
• Disciplina: 615/.780835
• Soggetti: Pediatric psychopharmacology; Adolescent psychopharmacology
• Lingua di pubblicazione: Inglese
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Note generali: Description based upon print version of record.
• Nota di bibliografia: Includes bibliographical references and index.
• Nota di contenuto: Intro -- CLINICAL ASPECTS OF PSYCHOPHARMACOLOGY IN CHILDHOOD AND ADOLESCENCE -- CLINICAL ASPECTS OF PSYCHOPHARMACOLOGY IN CHILDHOOD AND ADOLESCENCE -- Contents -- Foreword -- Introduction: pediatric psychopharmacology -- Modern psychopharmacology -- Conclusions -- References -- Section One: ADHD -- Chapter I Attention deficit hyperactivity disorder: pharmacologic management in children and adolescents -- Introduction -- Assessment and treatment principles -- Diagnostic criteria -- Diagnostic work up -- Comorbidity -- Discussing medications and monitoring with patients and caretakers -- Treatment planning and multimodal options -- Psychopharmacology of ADHD -- FDA approved stimulants -- Methylphenidate (MPH) preparations -- Oral short acting MPH formulations (3 - 5 hours duration) -- Multimodal treatment study of children with ADHD (MTA) study -- Preschool ADHD treatment study (pats) -- Other MPH IR formulations -- Oral intermediate acting MPH formulations (up to 8 hours duration) -- Long acting MPH formulations (up to 12 hours duration) -- MPH transdermal formulation (MTS) -- Amphetamine (AMP) preparations -- Short acting AMP formulations (up to 6 hours) -- Long acting AMP formulations (up to 8-10hHrs) -- Prodrug formulation -- Special safety considerations regarding stimulants -- Cardiovascular -- Growth -- Abuse potential -- Tics -- FDA approved non stimulants -- Atomoxetine (strattera) -- Guanfacine XRr (intuniv) -- Non FDA ; approved treatments -- Monitoring tools -- ADHD pharmacotherapy FaQs -- Conclusions -- Acknowledgments -- References -- Chapter II Attention deficit hyperactivity disorder and comorbid substance abuse -- Introduction -- Epidemiology -- Patterns of prescription stimulant medications -- Can childhood ADHD contribute to adolescent substance abuse? -- Detecting comorbid ADHD and SUD -- Clinical considerations.; Minimizing risks -- Impact of treatment on course of sud -- ADHD medications with low abuse potential -- Behavioral treatments -- Clinical management -- Conclusions -- References -- Section Two: Mental Health Aspects -- Chapter III Psychotherapy in the age of pharmacology -- Introduction -- A literature review -- Pharmacotherapy -- Psychotherapy -- Conclusions -- References -- Chapter IV Child and adolescent depression -- Introduction -- Epidemiology -- Clinical features -- Comorbid conditions -- Treatment -- Conclusions -- References -- Chapter V Pediatric bipolar disorder -- Introduction -- Epidemiology -- Clinical features -- Comorbid conditions -- Treatment -- Medication management -- Acute-phase treatment -- Maintenance treatment -- Treatment of comorbid disorders -- Conclusion -- References -- Chapter VI Anxiety disorders in children and adolescents -- Introduction -- Epidemiology -- Clinical features -- Treatment -- Selective serotonin re-uptake inhibitorsc (SSRIs) -- SSRI adverse effects -- Serotonin and nor-epinephrine re-uptake inhibitors -- Benzodiazepines -- Tricyclic antidepressants -- Buspirone -- Beta-blockers -- Hydroxyzine -- Mirtazepine and nefazodone -- Conclusions -- Acknowledgments -- References -- Chapter VII Oppositional defiant and conduct disorders -- Introduction -- Epidemiology -- Clinical features -- Comorbid conditions -- Treatment -- Non-medication treatments -- Medication treatments -- Psychostimulants -- Atomoxetine -- Lithium -- Atypical antipsychotics (AAs) -- Non-lithium mood stabilizers -- Other medications -- Conclusions -- References -- Chapter VIII Aggressive and violent behavior -- Introduction -- Epidemiology -- Clinical features -- Comorbid conditions -- Rule-out medical disorders -- Rule-out substance use disorders (SUDs) -- Identify psychiatric disorders -- Disruptive behavior disorders (DBDs).; Mood disorders -- Anxiety disorders -- Psychotic disorders -- Impulse control disorders -- Tic disorders -- Personality disorders -- Treatment -- Conclusions -- References -- Chapter IX Tic disorders in children and adolescents -- Introduction -- Definitions -- Epidemiology -- Differential diagnosis/comorbidity -- Psychopharmacology of tic disorders -- Alpha agonists -- Antipsychotics -- Dopamine receptor agonists -- Baclofen -- Stimulants -- Antidepressants -- Anticonvulsants -- Others -- Conclusions -- Acknowledgments -- References -- Section Three: Specific Disorders -- Chapter X Autistic spectrum disorders -- Introduction -- Epidemiology -- Clinical features -- Etiology -- Assessment -- Treatment -- Conclusions -- References -- Chapter XI Schizophrenia in children and adolescents -- Introduction -- Epidemiology -- Clinical features -- Important considerations while diagnosing childhood schizophrenia -- Assessment -- Rating and diagnostic scales -- Comorbid conditions -- Treatment -- Psychopharmacology -- Atypical antipsychotics -- Clozapine -- Typical Antipsychotics -- Depot injections of medication -- Psychosocial interventions -- Conclusion -- References -- Chapter XII Cognitive-adaptive disabilities -- Introduction -- Epidemiology -- Clinical features -- Comorbid conditions -- Mood disorders -- Anxiety disorders -- Attention-deficit/hyperactivity disorder (ADHD) -- ; Psychotic disorders -- Other disorders -- Treatment -- Mood disorders -- Bipolar disorder -- Anxiety disorders -- Attention-deficit/hyperactivity disorder -- Psychotic disorders -- Conclusions -- References -- Section Four: Other Use -- Chapter XIII Substance abuse disorders in adolescents: pharmacologic management -- Introduction -- Alcohol -- Drug interactions -- Amphetamines -- Cocaine -- Opioids -- Heroin dependence management -- Conclusions -- Acknowledgments -- References.; Chapter XIV Smoking cessation and pharmacological agents -- Introduction -- Nicotine replacement therapy -- Nicotine inhaler -- Nicotine gum -- Nicotine lozenge -- Nicotine nasal spray -- Nicotine patch -- Bupropion SR -- Varenicline -- Second-line medications -- Clonidine -- Nortriptyline -- Conclusions -- References -- Chapter XV Sleep disorders in children and adolescents -- Introduction -- Epidemiology -- Evaluation -- Insomnia -- Excessive daytime sleepiness -- Narcolepsy -- Klein-levin syndrome -- Parasomnias -- Restless legs syndrome (RLS) -- Sleep disordered breathing -- Conclusion -- Acknowledgments -- References -- Section Five: Conclusions -- Chapter XVI Pediatric psychopharmacology: where do we go from here? -- Introduction -- Pediatric psychopharmacology: quo vadis? -- Benefit of psychopharmacologic versus psychological therapies -- Benefit of psychopharmacology in pediatric mental illness -- Hope versushHype of pharmaceutical companies' for-profit research -- Intervention of governments in research -- Impact of genetics on psychopharmacology -- Results of sleep research on pediatric mental health -- Training of primary care clinicians in mental health -- Conclusions -- References -- Section Six: Acknowledgments -- Chapter XVII About the editors -- Chapter XVIII About the Department of Pediatrics and Human Development, Michigan State University College of Human Medicine, MSU/Kalamazoo Center for Medical Studies, Kalamazoo, Michigan, United States -- Mission and service -- Research activities -- Chapter XIX About the National Institute of Child Health and Human Development in Israel -- Mission -- Service and academic activities -- Research activities -- National collaboration -- International collaboration -- Targets -- Chapter XX About the book series "Health and human development".; Clinical aspects of psychopharmacology in childhood and adolescence -- Index -- Blank Page.